Literature DB >> 22454888

Bioavailability of digoxin from rapidly dissolving preparations.

B F Johnson1, S Lader.   

Abstract

1 Intestinal absorption of digoxin was assessed by determination of peak plasma concentrations, areas under plasma concentration curves over 80 h, and 10 day urinary excretion. Absorption was equal after ingestion of single doses of standard Lanoxin (Wellcome) tablets, tablets and capsules of ultra-rapid dissolution rate material, or an oral solution of digoxin in water. 2 Mean plasma concentrations and dosage-interval urinary excretion were highly similar during 14 day courses of either Lanoxin or ultra-rapid dissolution tablets. Increased bioavailability does not result from encapsulation of solid dosage presentations, nor from increasing tablet dissolution rate beyond 75% in 15 minutes. 3 Fourteen day courses of tablets of slow dissolution rate produced lower and less consistent mean plasma concentrations and urinary excretion. Slow dissolution rates are associated with greater individual variability in absorption.

Entities:  

Year:  1974        PMID: 22454888      PMCID: PMC1402428          DOI: 10.1111/j.1365-2125.1974.tb00262.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  A TRIAL OF SLOW-RELEASE TABLETS OF FERROUS SULPHATE.

Authors:  P CROSLAND-TAYLOR; D H KEELING; B W CROMIE
Journal:  Curr Ther Res Clin Exp       Date:  1965-04

2.  Rate of dissolution of digoxin tablets as a predictor of absorption.

Authors:  B F Johnson; H Greer; J McCrerie; C Bye; A Fowle
Journal:  Lancet       Date:  1973-06-30       Impact factor: 79.321

3.  Correlation of digoxin-tablet dissolution-rate with biological availability.

Authors:  J Lindenbaum; V P Butler; J E Murphy; R M Cresswell
Journal:  Lancet       Date:  1973-06-02       Impact factor: 79.321

4.  Variation in the biological availability of digoxin.

Authors:  T R Shaw; M R Howard; J Hamer
Journal:  Lancet       Date:  1972-08-12       Impact factor: 79.321

5.  Serum-digoxin concentrations during treatment with different preparations.

Authors:  V Manninen; J Melin; G Hartel
Journal:  Lancet       Date:  1971-10-23       Impact factor: 79.321

6.  Evaluation of digoxin bioavailability in single-dose studies.

Authors:  D J Greenblatt; D W Duhme; J Koch-Weser; T W Smith
Journal:  N Engl J Med       Date:  1973-09-27       Impact factor: 91.245

7.  Absorption of orally given digoxin preparations.

Authors:  D H Huffman; D L Azarnoff
Journal:  JAMA       Date:  1972-11-20       Impact factor: 56.272

8.  Therapeutic non-equivalence of digoxin tablets in the United Kingdom: correlation with tablet dissolution rate.

Authors:  T R Shaw; K Raymond; M R Howard; J Hamer
Journal:  Br Med J       Date:  1973-12-29

9.  Variation in biologic availability of digoxin from four preparations.

Authors:  J Lindenbaum; M H Mellow; M O Blackstone; V P Butler
Journal:  N Engl J Med       Date:  1971-12-09       Impact factor: 91.245

10.  Biological availability of digoxin from Lanoxin produced in the United Kingdom.

Authors:  B F Johnson; A S Fowle; S Lader; J Fox; A D Munro-Faure
Journal:  Br Med J       Date:  1973-11-10
  10 in total
  3 in total

Review 1.  Serum concentration monitoring of cardiac glycosides. How helpful is it for adjusting dosage regimens?

Authors:  R J Dobbs; C J O'Neill; A A Deshmukh; P W Nicholson; S M Dobbs
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

2.  Prediction of digoxin dose requirements.

Authors:  S M Dobbs; G E Mawer
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

3.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.